-
Posted by
Two Blokes May 27 -
Filed in
Stock
-
5 views
MannKind's stock decline is likely due to concerns over Tyvaso DPI competition from Liquidia, but I believe these fears are exaggerated. Tyvaso DPI provides MannKind with a stable revenue base, supporting its focused pipeline and future growth opportunities. MannKind's Technosphere technology holds promise for additional partnerships beyond United Therapeutics, enhancing long-term potential.
